|
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results indicated that PPARγ might be crucial for BCa tumorigenesis by interfering with the motility and viability of BCa cells.
|
30912275 |
2019 |
|
Bladder Neoplasm
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Author Correction: Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.
|
31164653 |
2019 |
|
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our study reveals genomic alterations of PPARG that lead to pro-tumorigenic PPARγ/RXRα pathway activation in luminal bladder tumors and may open the way towards alternative options for treatment.
|
30651555 |
2019 |
|
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer.
|
31358595 |
2019 |
|
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Repression of transcription factor AP-2 alpha by PPARγ reveals a novel transcriptional circuit in basal-squamous bladder cancer.
|
31772149 |
2019 |
|
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
We showed that PPARγ was a favorable prognostic factor in patients with bladder cancer.
|
30845932 |
2019 |
|
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Two travel awards were presented to H. Yamashita (USA) for his submission on peroxisome proliferator-activated receptor gamma-mediated repression of transcription factor activating protein 2 alfa expression identifying a transcriptional circuit in basal-squamous bladder cancer in a cell line model.S.B.
|
30852032 |
2019 |
|
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Finally, the prognostic significance of PPAR-γ and PTEN for bladder cancer was validated <i>in vivo</i> using clinical samples.
|
31555390 |
2019 |
|
Bladder Neoplasm
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
<b>Aims:</b> Whether pioglitazone (PIO), a peroxisome proliferator-activated receptor-gamma agonist, increases the risk of developing bladder cancer has been debated for several years.
|
29483814 |
2018 |
|
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our results offer a preclinical proof of concept for PPARG as a candidate therapeutic target in bladder cancer.<i></i>.
|
28923856 |
2017 |
|
Bladder Neoplasm
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.
|
28740126 |
2017 |
|
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Alteration of PPARγ expression by PPARγ-small interfering ribonucleic acid or activation by its agonist rosiglitazone, a diabetic thiazolidinedione drug, could lead to alternation of BCa cell migration and invasion.
|
23522297 |
2013 |
|
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results suggest that PPARγ agonist DIM-C can be an excellent alternative to bladder tumors resistant to EGFR inhibition and combination efficacy might be achieved in a schedule-specific manner.
|
23409107 |
2013 |
|
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Role of peroxisome proliferator activated receptor-gamma in bacillus Calmette-Guérin bladder cancer therapy.
|
23088980 |
2012 |
|
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
RGD |
Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.
|
18712722 |
2008 |
|
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Our results show that BCG induced the cytoplasmatic expression of PPARgamma in bladder tumor cells in vitro and in vivo.
|
16391825 |
2006 |
|
Bladder Neoplasm
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Using the TaqMan method, we genotyped single nucleotide polymorphisms in interleukin (IL) -6 (-174 G-->C), IL-8 (-251 T-->A), tumor necrosis factor-alpha (TNF-alpha; -308 G-->A), and peroxisome proliferator-activated receptor gamma (PPARG; Pro12Ala), and determined their associations with BC initiation and clinical outcome.
|
16110031 |
2005 |
|
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells.
|
11980898 |
2002 |
|
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We examined the expression of PPARgamma in normal urothelium and bladder cancer in an attempt to assess its functional role.
|
11485917 |
2001 |
|
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
The role of peroxisome proliferator-activated receptor gamma in bladder cancer in relation to angiogenesis and progression.
|
11888683 |
2000 |
|
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Troglitazone also induced an endogenous PPARgamma target gene in T24 cells, adipocyte-type fatty acid binding protein (A-FABP), the expression of which correlates with bladder cancer differentiation.
|
10935488 |
1999 |